XWELL, Inc. (XWEL) AI Stock Analysis
XWEL AI stock analysis summary
AI ResearchXWELL, Inc. (XWEL) operates health, wellness, and diagnostic services primarily located in airport terminals. In FY2025, the company generated revenue of $29.2M with net income of -$17.0M, down from $73.7M in FY2021. For the trailing twelve months ended June 30, 2026, revenue stood at $28.3M alongside an operating margin of -26.1%.
- Market cap
- $7.3M
- Revenue (TTM)
- $28.3M
- P/E
- — fwd 10.8x
- 1Y return
- -27.0% S&P 500 16.8%
- Avg. target
- $7.00 858.9% vs last close
Bull case
- XWELL maintains a net cash position of $4.5M as of June 30, 2026, supported by $11.8M in cash and short-term investments against $7.3M in total debt.
- The stock's forward P/E of 10.8x and price-to-sales ratio of 0.3x trade at a discount to the US-listed Healthcare peer medians of 17.3x and 4.1x.
- The mean analyst price target of $7.00 indicates an 858.9% premium over the closing price of $0.73 on October 16, 2026.
Bear case
- Free cash flow has remained negative for four consecutive years, including -$11.7M in FY2025 and -$12.8M in FY2024.
- Shareholders' equity is negative at -$1.9M as of June 30, 2026, with a trailing twelve-month profit margin of -82.9%.
- Over the past five years, XWEL shares fell 97.4%, underperforming the S&P 500 return of 83.0%.
What XWELL does
XWELL, Inc., formerly known as XpresSpa Group, Inc., provides spa and medical diagnostic services primarily across airport terminals under brands such as XpresSpa, XpresTest, Treat, and HyperPointe. Its spa offerings include massage therapy, nail care, skincare treatments, and retail travel-related products. In addition, XWELL operates airport wellness centers providing diagnostic screening and rapid testing for communicable diseases including COVID-19, influenza, and RSV, along with seasonal flu vaccinations. As of December 31, 2021, the company operated 52 spa and clinic locations across 24 airports in the United States, the Netherlands, and the United Arab Emirates.
Growth and profitability
XWELL experienced top-line volatility over recent years, with revenue dropping from $73.7M in FY2021 to $55.9M in FY2022 and $30.1M in FY2023. While revenue rebounded 12.6% to $33.9M in FY2024, it fell 13.8% in FY2025 to $29.2M. Gross margin contracted from 43.9% in FY2021 to 22.7% in FY2025, while operating margin shifted from 5.6% to -32.0%. The company posted net income of $3.3M in FY2021, followed by net losses with net income of -$32.8M in FY2022, -$27.7M in FY2023, -$16.9M in FY2024, and -$17.0M in FY2025. In the latest quarter ended June 30, 2026, quarterly revenue fell 7.1% year-over-year.
Balance sheet and cash flow
As of June 30, 2026, XWELL held cash and short-term investments of $11.8M and total debt of $7.3M, yielding net cash of $4.5M. Total assets stood at $20.5M with a current ratio of 2.27, while shareholders' equity was -$1.9M. Operating cash flow was -$8.7M in FY2025 alongside free cash flow of -$11.7M. For FY2025, capital expenditures were $3.0M, share buybacks totaled $1.8M, and dividends paid were $267,000.
Valuation and performance
XWELL trades at an enterprise value of $3.3M and a market capitalization of $7.3M. The stock trades at an EV-to-EBITDA multiple of 0.5x, compared to the median of 12.0x for its US-listed Healthcare peers. Its price-to-sales ratio is 0.3x versus the peer median of 4.1x, and its forward P/E is 10.8x against the peer median of 17.3x. Over the past year, XWEL shares fell 27.0%, underperforming the S&P 500 return of 16.8%. Over a 5-year period, the stock fell 97.4%, compared to an 83.0% gain for the S&P 500.
What analysts expect
Wall Street analyst coverage reflects a mean price target of $7.00 for XWELL, representing an 858.9% increase from the last close of $0.73 on October 16, 2026. Across recent reporting periods, the company recorded 3 EPS beats out of the last 4 quarters. The next earnings date is set for November 13, 2026.
Key risks and what to watch
- Ongoing operational cash burn is reflected by an operating cash flow of -$8.7M in FY2025.
- Negative shareholders' equity of -$1.9M indicates capital erosion from repeated annual net losses.
- Quarterly revenue fell 7.1% year-over-year in the period ending June 30, 2026, indicating continued top-line pressure.
AI-generated research summary. Written with AI from Quotelinks data as of October 16, 2026 and checked so every figure matches that data. For information only, not investment advice. Disclaimer
About this XWEL AI stock analysis
This page is an AI-written research summary of XWELL, Inc. (XWEL). The text was generated on October 30, 2026 from Quotelinks data as of October 16, 2026 (company profile, annual results, latest balance sheet, valuation, price performance and analyst estimates). An automatic check rejects any draft that contains a figure not found in that data. It is not investment advice; verify figures on the linked tabs before making decisions.
Related: XWEL income statement, XWEL balance sheet, XWEL key metrics, XWEL chart. See the XWEL stock overview for the latest quote and news.
XWEL AI stock analysis FAQ
What is XWELL's ticker and stock exchange?
XWELL trades on the NASDAQ exchange under the ticker symbol XWEL.
What is XWELL's current cash and debt position?
As of June 30, 2026, XWELL reported $11.8M in cash and short-term investments, $7.3M in total debt, and a net cash balance of $4.5M.
What is the analyst price target for XWEL stock?
The mean price target for XWEL is $7.00, which is 858.9% above the last closing price of $0.73 on October 16, 2026.
When is XWELL's next earnings report date?
XWELL is scheduled to report its next earnings on November 13, 2026.